Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS016
MIFTS: 42

Plasma Cell Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Plasma Cell Leukemia

About this section

MalaCards integrated aliases for Plasma Cell Leukemia:

Name: Plasma Cell Leukemia 53 59 55
Leukemia, Plasma Cell 53 73
Pcl 59

Characteristics:

Orphanet epidemiological data:

59
plasma cell leukemia
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly; Age of death: adult,elderly;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34 33
Orphanet: 59  
Rare haematological diseases


External Ids:

Orphanet 59 ORPHA454714
UMLS via Orphanet 74 C0023484
ICD10 via Orphanet 34 C90.1
ICD10 33 C90.1
Sources

Summaries for Plasma Cell Leukemia

About this section
NIH Rare Diseases : 53 Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma that involves high levels of plasma cells circulating in the peripheral blood. The signs and symptoms of PCL include aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers. Different types of treatments are available for patients with PCL. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. For detailed information on the available treatment options, please visit the following link. http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/Patient/page4

MalaCards based summary : Plasma Cell Leukemia, also known as leukemia, plasma cell, is related to lymphoma, mucosa-associated lymphoid type and myeloma, multiple. An important gene associated with Plasma Cell Leukemia is CCND1 (Cyclin D1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Interleukin-4 and 13 signaling. The drugs Doxorubicin and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and testes, and related phenotype is vision/eye.

Wikipedia : 76 Plasma cell leukemia (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant... more...

Sources

Related Diseases for Plasma Cell Leukemia

About this section

Diseases related to Plasma Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Related Disease Score Top Affiliating Genes
1 lymphoma, mucosa-associated lymphoid type 29.2 CCND1 IRF4
2 myeloma, multiple 28.7 CCND1 FGFR3 IRF4 MAF NCAM1
3 lymphedema, hereditary, ia 11.2
4 plasmacytic leukemia 11.1
5 leukemia 10.8
6 lymphoma 10.1
7 plasmacytoma 10.1
8 chondromyxoid fibroma 10.0 CCND1 FGFR3
9 prostatitis 9.9
10 personality disorder 9.9
11 prostate cancer 9.9
12 monoclonal gammopathy of uncertain significance 9.9
13 bladder urothelial carcinoma 9.9 CCND1 FGFR3
14 angioimmunoblastic t-cell lymphoma 9.8
15 follicular lymphoma 9.8 CCND1 IRF4
16 papilloma 9.8 CCND1 FGFR3
17 antisocial personality disorder 9.8
18 gastric cancer 9.8
19 neuroendocrine tumor 9.8
20 colorectal cancer 9.8
21 post-traumatic stress disorder 9.8
22 lung cancer 9.8
23 leukemia, chronic myeloid 9.7
24 human herpesvirus 8 9.7
25 hematopoietic stem cell transplantation 9.7
26 macroglobulinemia 9.7
27 peripheral t-cell lymphoma 9.7
28 amyloidosis 9.7
29 myelofibrosis 9.7
30 meningitis 9.7
31 epithelial predominant wilms' tumor 9.6 MAF NCAM1
32 nephrogenic adenofibroma 9.6 MAF NCAM1
33 bile duct carcinoma 9.6 CCND1 NCAM1
34 extramedullary plasmacytoma 9.6
35 leukemia, acute myeloid 9.6
36 leukemia, b-cell, chronic 9.6
37 cranial nerve palsy 9.6
38 splenomegaly 9.6
39 hepatitis c virus 9.6
40 disseminated intravascular coagulation 9.6
41 restrictive cardiomyopathy 9.6
42 back pain 9.6
43 nephrotic syndrome 9.6
44 pancreatitis 9.6
45 dengue virus 9.6
46 pneumonia 9.6
47 ovarian serous cystadenocarcinoma 9.6
48 pulmonary hypertension 9.6
49 paraplegia 9.6
50 leukemia, chronic lymphocytic 2 9.6

Graphical network of the top 20 diseases related to Plasma Cell Leukemia:



Diseases related to Plasma Cell Leukemia
Sources

Symptoms & Phenotypes for Plasma Cell Leukemia

About this section

MGI Mouse Phenotypes related to Plasma Cell Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 8.92 CCND1 FGFR3 MAF NCAM1
Sources

Drugs & Therapeutics for Plasma Cell Leukemia

About this section

Drugs for Plasma Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
2
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
3
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
4
Lenograstim Approved, Investigational Phase 1, Phase 2,Phase 2 135968-09-1
5
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
6
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
7
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
8
Fludarabine Approved Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
9
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
10
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
11
Allopurinol Approved Phase 2 315-30-0 2094
12
Cytarabine Approved, Investigational Phase 2,Phase 1 147-94-4 6253
13
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
15
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
16
Acetaminophen Approved Phase 2 103-90-2 1983
17
Everolimus Approved Phase 2 159351-69-6 6442177
18
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
19
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
20
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
21
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
22
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
23
Promethazine Approved, Investigational Phase 2 60-87-7 4927
24
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
25
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
26
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
27 Pomalidomide Approved Phase 2 19171-19-8
28 Ixazomib Approved, Investigational Phase 2,Phase 1 1072833-77-2
29
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 32326 21704
30
Daratumumab Approved Phase 2 945721-28-8
31
Pegaspargase Approved, Investigational Phase 2 130167-69-0
32
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 77-92-9 311
33
Glycine Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 56-40-6 750
34 tannic acid Approved, Nutraceutical Phase 2
35
Doxil Approved June 1999 Phase 2 31703
36 Dexamethasone acetate Phase 2,Phase 1 1177-87-3
37 interferons Phase 2
38 glucocorticoids Phase 2,Phase 1
39
protease inhibitors Phase 2,Phase 1
40 Gastrointestinal Agents Phase 2,Phase 1
41 HIV Protease Inhibitors Phase 2,Phase 1
42 Topoisomerase Inhibitors Phase 2,Phase 1
43 Hormone Antagonists Phase 2,Phase 1
44 Hormones Phase 2,Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
46 Peripheral Nervous System Agents Phase 2,Phase 1
47 Anti-Bacterial Agents Phase 2,Phase 1
48 Antibiotics, Antitubercular Phase 2,Phase 1
49 Immunoglobulin A Phase 2
50 Antiemetics Phase 2,Phase 1

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Unknown status NCT01328236 Phase 2 Bortezomib;Liposome doxorubicin;Dexamethasone
2 Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Unknown status NCT01435720 Phase 1, Phase 2
3 Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia Completed NCT01553357 Phase 2 Lenalidomide, dexamethasone
4 Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 Completed NCT02858999 Phase 2 PAD-VCD
5 Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants Completed NCT00307086 Phase 2 Bortezomib;Melphalan
6 A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00821249 Phase 1, Phase 2 ARRY-520, KSP(Eg5) inhibitor; intravenous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;Dexamethasone, steroid; oral
7 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT02547662 Phase 2 Dexamethasone;Ixazomib Citrate;Pomalidomide
8 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
9 Allo HSCT Using RIC for Hematological Diseases Recruiting NCT02661035 Phase 2 Allopurinol;Fludarabine;Cyclophosphamide;ATG;Tacrolimus;MMF
10 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Recruiting NCT03314974 Phase 2
11 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
12 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Recruiting NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
13 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
14 MUK Nine b: OPTIMUM Treatment Protocol Not yet recruiting NCT03188172 Phase 2 Cyclophosphamide;Bortezomib;Lenalidomide;Daratumumab;Dexamethasone;Melphalan;Filgrastim
15 Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen Terminated NCT00615589 Phase 2 Fludarabine/Busulfan x 4 days
16 Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma Terminated NCT01658904 Phase 1, Phase 2 Carfilzomib;Melphalan;Filgrastim
17 Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies Terminated NCT00837200 Phase 2 Oncaspar, Doxil, Decadron
18 Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Withdrawn NCT03100877 Phase 1, Phase 2 Cyclophosphamide;Lenalidomide;Melphalan
19 A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT01248923 Phase 1 ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Dexamethasone, steroid; oral;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
20 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed NCT00258245 Phase 1 arsenic trioxide;bortezomib;dexamethasone;thalidomide;Aspirin
21 Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Recruiting NCT02504359 Phase 1 Carmustine;Cytarabine;Etoposide;Ixazomib Citrate;Melphalan;Methotrexate;Tacrolimus
22 SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Recruiting NCT02334865 Phase 1 Lenalidomide
23 MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Recruiting NCT03031730 Phase 1 Carfilzomib;Dexamethasone;Lenalidomide;MDM2 Inhibitor AMG-232
24 Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma Active, not recruiting NCT01372540 Phase 1 Arry-520;Carfilzomib;Dexamethasone;Filgrastim
25 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies Active, not recruiting NCT00988013 Phase 1
26 Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma Withdrawn NCT02315157 Phase 1 Bendamustine
27 High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT03389347 Not Applicable
28 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Recruiting NCT01962636 Not Applicable Fludarabine;Cyclophosphamide;Cyclosporine A;Mycophenylate mofetil

Search NIH Clinical Center for Plasma Cell Leukemia

Sources

Genetic Tests for Plasma Cell Leukemia

About this section
Sources

Anatomical Context for Plasma Cell Leukemia

About this section

MalaCards organs/tissues related to Plasma Cell Leukemia:

41
Bone Marrow, Bone, Testes, T Cells, B Cells, Kidney, Skin
Sources

Publications for Plasma Cell Leukemia

About this section

Articles related to Plasma Cell Leukemia:

(show top 50) (show all 394)
# Title Authors Year
1
A rare case of a minimally secretory plasma cell leukemia with a hemorrhagic gastric plasmacytoma. ( 29892544 )
2018
2
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome. ( 29501828 )
2018
3
Lymphoplasmacytoid cytology in plasma cell leukemia. ( 29027254 )
2018
4
Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy. ( 29582109 )
2018
5
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. ( 29523783 )
2018
6
Primary Nonsecretory Plasma Cell Leukemia With Multiple Chromosomal Abnormalities: A Case Report. ( 29664669 )
2018
7
Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia. ( 29417202 )
2018
8
Plasma Cell Leukemia Masquerading as a Relapse of the Nephrotic Syndrome. ( 29401321 )
2018
9
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. ( 29965787 )
2018
10
Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). ( 29064593 )
2018
11
Plasma cell leukemia presenting as &amp;quot;lymphocytosis&amp;quot;. ( 29699997 )
2018
12
Acute Renal failure caused by plasma cell infiltration in primary plasma cell leukemia. ( 28792128 )
2017
13
Leukemia Cutis Associated with Secondary Plasma Cell Leukemia. ( 28620566 )
2017
14
Progression of cutaneous plasmacytoma to plasma cell leukemia in a dog. ( 28186653 )
2017
15
Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient. ( 28286633 )
2017
16
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). ( 29108331 )
2017
17
Flaming plasma cell leukemia. ( 28120778 )
2017
18
IgM Myeloma with Plasma Cell Leukemia: Case Report and Literature Review. ( 29066491 )
2017
19
A case of primary plasma cell leukemia exhibiting hemophagocytic plasma cells relapsed with multiple cutaneous plasmacytoma. ( 29333413 )
2017
20
Plasmacytomas and Plasma-Cell Leukemia. ( 28296609 )
2017
21
Plasma Cell Leukemia Presenting with Hyperleukocytosis and Anaplasia. ( 28194071 )
2017
22
Histone deacetylase inhibitors in plasma cell leukemia treatment: Effect of bone marrow microenvironment. ( 28043150 )
2017
23
Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. ( 28255016 )
2017
24
Morphological Transformation of Myeloma Cells into Multilobated Plasma Cell Nuclei within 7 Days in a Case of Secondary Plasma Cell Leukemia That Finally Transformed as Anaplastic Myeloma. ( 29430310 )
2017
25
Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma - a diagnostic challenge solved by flow cytometry. ( 28270351 )
2017
26
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. ( 28544116 )
2017
27
Rapid Fatal Acute Peripheral T-Cell Lymphoma Associated With IgG Plasma Cell Leukemia and IgA Hypergammaglobulinemia. ( 27824644 )
2016
28
Primary plasma cell leukemia 2.0: advances in biology and clinical management. ( 27759436 )
2016
29
Plasma cell leukemia: Single institution experience. ( 28485366 )
2016
30
Primary Plasma Cell Leukemia: Identity Card 2016. ( 26995215 )
2016
31
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. ( 28038447 )
2016
32
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. ( 26505781 )
2016
33
Hemorrhagic Skin Nodules and Plaques: A Diagnostic Clue to Underlying Primary Plasma Cell Leukemia. ( 27057024 )
2016
34
Primary plasma cell leukemia: A report of two cases of a rare and aggressive variant of plasma cell myeloma with the review of literature. ( 27721294 )
2016
35
Confusing Hairy Cells in a Case of IgG Kappa Plasma Cell Leukemia. ( 27215099 )
2016
36
Progress in the Treatment of Primary Plasma Cell Leukemia. ( 27114588 )
2016
37
Plasma Cell Leukemia With Prominent Hairy-cell Morphology. ( 27916226 )
2016
38
Radiographic features of plasma cell leukemia in the maxilla: A case report. ( 28035306 )
2016
39
Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. ( 27103978 )
2016
40
MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32). ( 27446453 )
2016
41
Multiple myeloma and secondary plasma cell leukemia. ( 27833979 )
2016
42
Plasma cell leukemia revealing a G6PD deficiency. ( 28034875 )
2016
43
Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature. ( 27104188 )
2016
44
Plasma Cell Leukemia Presenting as a Chest Wall Mass: A Case Report. ( 27462235 )
2016
45
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du MyAclome. ( 27114594 )
2016
46
Plasma cell leukemia mimicking acute myeloid leukemia. ( 28092885 )
2016
47
Abrupt Development of Plasma Cell Leukemia in a Patient with Chronic Anemia under Follow-up. ( 26702753 )
2016
48
Novel Agents for the Treatment of Primary Plasma-Cell Leukemia: Lights and Shadows. ( 26506015 )
2016
49
Plasma cell leukemia: update on biology and therapy. ( 27819179 )
2016
50
Characterization of a new human plasma cell leukemia cell line UHKT-944. ( 25600340 )
2015
Sources

Variations for Plasma Cell Leukemia

About this section
Sources

Expression for Plasma Cell Leukemia

About this section
Search GEO for disease gene expression data for Plasma Cell Leukemia.
Sources

Pathways for Plasma Cell Leukemia

About this section

Pathways related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 12.03 CCND1 FGFR3 IRF4 NCAM1
2
Interleukin-4 and 13 signaling 66
11.51 CCND1 IRF4
3
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 11.51 CCND1 FGFR3
4
Innate Lymphoid Cell Differentiation Pathways 65
11.34 IRF4 NCAM1
5
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.3 FGFR3 NCAM1
6
C-MYB transcription factor network 1
11.26 CCND1 MAF
7
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.14 IRF4 MAF
8
Dendritic Cells Developmental Lineage Pathway 65
11.02 IRF4 NCAM1
9
Bladder cancer 37 1
10.82 CCND1 FGFR3
Sources

GO Terms for Plasma Cell Leukemia

About this section

Biological processes related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 8.62 IRF4 NCAM1

Molecular functions related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.62 FGFR3 NCAM1
Sources

Sources for Plasma Cell Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....